Creation of a Network to Promote Universal Screening for Lynch Syndrome: The Lynch Syndrome Screening Network
- 420 Downloads
The Evaluation of Genomic Applications in Practice and Prevention Working Group published an evidence-based recommendation stating that every newly diagnosed colorectal cancer (CRC) should undergo tumor screening for Lynch syndrome (LS). In 2011, leading cancer institutions and public health agencies created the Lynch Syndrome Screening Network (LSSN) in order to promote routine LS screening on all newly diagnosed CRCs and endometrial cancers (EC). The LSSN facilitates implementation of appropriate screening via shared resources, protocols and data through network collaboration. The LSSN website contains resources for institutions interested in initiating screening, including materials for program development, implementation and sustainability. The LSSN listserv gives providers access to experts in LS screening and implementation. The LSSN database will allow exploration of key gaps in implementation as a consortia-wide endeavor. To date, the LSSN’s membership includes 85 institutions involved in the care of CRC patients and nine official partners such as national and state public health entities and other non-profit institutions. Nearly 80 % of the LSSN’s members have already implemented routine or universal CRC and/or EC screening. LSSN serves to further the population health potential of universal LS screening through collaborative efforts and resources.
KeywordsLynch syndrome Universal screening Colon cancer Endometrial cancer Genetic testing Genetic counseling
Support for logistical needs of the LSSN has been provided in part by the NCI’s Epidemiology and Genomics Research Program (EGRP) in the Division of Cancer Control and Population Sciences (DCCPS). Support for Deborah Cragun’s work was provided by an NCI training grant to Moffitt Cancer Center (R25T 5R25CA147832-04).
Conflict of Interest
Sarah Mange, Cecelia Bellcross, Deborah Cragun, Deb Duquette, Lisa Gorman, Heather Hampel, Kory Jasperson declare that they have no conflict of interest.
- Beamer, L. C., Grant, M. L., Espenschied, C. R., Blazer, K. R., Hampel, H. L., Weitzel, J. N., et al. (2012). Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. Journal of Clinical Oncology, 30, 1058–1063.CrossRefGoogle Scholar
- Bellcross, C. A., Bedrosian, S. R., Daniels, E., Duquette, D., Hampel, H., Jasperson, K., et al. (2012). Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Genetics in Medicine, 14, 152–162.CrossRefGoogle Scholar
- Bonis, P. A., Trikalinos, T. A., Chung, M., Chew, P., Ip, S., DeVine, D. A., et al. (2007). Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. Evidence Report/Technology Assessment, 150, 1–180.Google Scholar
- Cohen, S. A. (2013). Current Lynch Syndrome Tumor Screening Practices: A Survey of Genetic Counselors. Journal of Genetic Counseling, Published online, 15 May 2013.Google Scholar
- Cragun, D., DeBate, R. D., Hampel, H., Vadaparampil, S. T., Baldwin, J., Pal, T. (2013). Comparing universal Lynch syndrome tumor screening programs to evaluate associations between implementation strategies and patient follow-through. Unpublished manuscript.Google Scholar
- Evaluation of Genomic Applications in Practice and Prevention [EGAPP]. (2009). Recommendations from the EGAPP working group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine, 11, 35–41.CrossRefGoogle Scholar
- Healthypeople.gov (2013). Retrieved November 21, 2013, from http://www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=15.
- Howlader, N., Noone, A. M., Krapcho, M., Garshell, J., Neyman, N., Altekruse, S. F., et al. (April 2013). Estimated New Cancer Cases and Deaths for 2013. SEER Cancer Statistics Review, 1975–2010, National Cancer Institute. Retrieved December 2, 2013, from http://seer.cancer.gov/csr/1975_2010/.
- Järvinen, H. J., Renkonen-Sinisalo, L., Aktan-Collan, K., Peltomäki, P., Aaltonen, L. A., & Mecklin, J. P. (2009). Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. Journal of Clinical Oncology, 27, 4793–4797.CrossRefGoogle Scholar
- Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Rüschoff, J., et al. (2004). Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute, 96, 261–268.CrossRefGoogle Scholar